Description

DIVAA^™isthefirstinvivosystemforthestudyofangiogenesisthatprovidesquantitativeandreproducIBLeresults.Duringthecourseoftheassay,implantgradesiliconecylindersclosedatoneend,calledangioreactors,arefilledwith20μlofTrevigen’sPathClear®basementmembraneextract(BME)premixedwithorwithoutangiogenic-modulatingfactors*.Theseangioreactorsarethenimplantedsubcutaneouslyinthedorsalflankofnudemice.Accompaniedwiththeonsetofangiogenesis,vascularendothelialcellsproceedtogrowintotheBMEandformvesselsintheangioreactor.Asearlyasninedayspost-implantation,thereareenoughcellstodetermineaneffectivedoseresponsetoangiogenicmodulatingfactors.Thesleekdesignoftheangioreactorprovidesastandardizedplatformforreproducibleandquantifiableinvivoangiogenesisassays.Comparedtotheplugassay,theangioreactorpreventsassayerrorsduetoabsorptionofthebasementmembraneextractbythemouse.Inaddition,theangioreactorusesonlyafractionofthematerialsconservingbothBMEandtestcompoundsused,anduptofourangioreactorsmaybeimplantedineachmouse,allowingforgreaterstatisticalpower.Trevigen’sDIVAAhasbeenusedinavarietyofinvestigations.

*ThePathClear®designationmeans:

• Nobacterialorfungalgrowthdetectedafterincubationat37°Cfor14daysfollowingUSPXXIVChapter71sterilitytest.
• NegativebyPCRtestfor:mycoplasma,17bacterialandvirusstrainstypicallyincludedinmouseantibodyproduction(MAP)testing,plus13additionalmurineinfectiousagentsincludingLDEV,foratotalof31organismsandviruses.

Catalog#3450-048-Kincludes:
CatalogNumber	Description	Qty
3450-048-02	DIVAABME	1
3450-048-04	DIVAAFGF-2PositiveControl	1
3450-048-05	DIVAACellSperse	1
3450-048-B9	DIVAAFGF-2(300ng)/VEGF(100ng)	1
3450-048-01	DIVAAAngioreactor	1
3450-048-03	DIVAAWashBuffer	1
3450-048-06	DIVAAFITC-Lectin200X	1
3450-048-07	25XFITC-LectinDiluent	1
3450-048-08	HeparinSolution	1

Trevigen，Inc.是一家发展迅速的生物技术公司，致力于开发用于癌症研究，药物发现，遗传毒理学，再生医学和干细胞研究的产品和技术。我们提供试剂盒和试剂，用于研究DNA损伤和修复，细胞凋亡，氧化应激，癌细胞行为，3D培养和干细胞。该公司获得了美国国立卫生研究院（National Institutes of Health）多项SBIR资助。